CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Safety and tolerability of exenatide once weekly pooled summary of 1095 patients from DURATION-1, 2 and 3
DOI 10.1055/s-0031-1277484
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Lee, J Han, C Brown, J Ferguson, O Bachmann
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Exenatide once weekly (EQW) provides extended release of exenatide, a GLP-1 receptoragonist, for the treatment of type 2 diabetes (T2DM). Methods: We provide a summary of the accumulated EQW safety based on pooled data from 3 completed randomized controlled trials including 1095 patients followed for 26–30 weeks on either EQW (N=541) or pooled comparators (PC: N=554) treated with sitagliptin, pioglitaz…
Zitieren
Zitierempfehlung
D Lee, J Han, C Brown, J Ferguson, O Bachmann (2011) Safety and tolerability of exenatide once weekly pooled summary of 1095 patients from DURATION-1, 2 and 3. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0031-1277484
Mit CareLit weiterarbeiten